Title :

Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials.

Author(s) :

Simpson, Eric L. [Auteur]
Oregon Health and Science University [Portland] [OHSU]
Merola, Joseph F. [Auteur]
Silverberg, Jonathan I. [Auteur]
The George Washington University [GW]
Reich, Kristian [Auteur]
Warren, Richard B. [Auteur]
NIHR Biomedical Research Centre [London]
staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Girolomoni, Giampiero [Auteur]
Università degli studi di Verona = University of Verona [UNIVR]
Papp, Kim [Auteur]
De Bruin-Weller, Marjolein [Auteur]
University Medical Center [Utrecht] [UMCU]
Thyssen, Jacob P. [Auteur]
University of Copenhagen = Københavns Universitet [UCPH]
Zachariae, Rebecca [Auteur]
Olsen, Christiana K. [Auteur]
Wollenberg, Andreas [Auteur]
Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München [LMU]

Journal title :

British Journal of Dermatology

Abbreviated title :

Br J Dermatol

Volume number :

187

Pages :

888–899

Publication date :

2022-09-20

ISSN :

1365-2133

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Tralokinumab, an anti‐interleukin‐13 biologic for the treatment of atopic dermatitis (AD), has provided significant and early improvements in signs and extent of AD in key Phase 3 clinical trials and was well tolerated, ...
Show more >Tralokinumab, an anti‐interleukin‐13 biologic for the treatment of atopic dermatitis (AD), has provided significant and early improvements in signs and extent of AD in key Phase 3 clinical trials and was well tolerated, with a safety profile comparable to placebo. This study comprehensively assessed the safety profile of tralokinumab using data from five placebo‐controlled trials in adult patients with moderate‐to‐severe AD, finding that overall incidence and rate of adverse events (AEs) was similar between tralokinumab and placebo in the initial treatment period (16 weeks) and did not increase over 52 weeks of continued treatment. Common AEs occurring more frequently with tralokinumab included conjunctivitis and injection site reaction.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-12T00:41:16Z
2024-01-31T10:15:05Z